These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23169230)

  • 1. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
    Giménez de Béjar V; Carballo-Cordero M
    Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
    Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
    Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
    [No Abstract]   [Full Text] [Related]  

  • 6. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F
    Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
    van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
    Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
    Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nocturnal continuous subcutaneous infusion of apomorphine in advanced Parkinson's disease: a series of 37 cases].
    García-Fernández C; Vargas-Mendoza AK; López-López B; Blázquez-Estrada M; Suárez-San Martín ME
    Rev Neurol; 2024 Oct; 79(8):217-221. PubMed ID: 39404035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine nodules in Parkinson's disease: best practice considerations.
    Todd A; James CA
    Br J Community Nurs; 2008 Oct; 13(10):457-63. PubMed ID: 19057470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T; Postma AG; Drent M
    Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
    [No Abstract]   [Full Text] [Related]  

  • 13. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
    Poltawski L; Edwards H; Todd A; Watson T; Lees A; James CA
    Mov Disord; 2009 Jan; 24(1):115-8. PubMed ID: 19006068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
    Cavallieri F; Fraix V; Meoni S; Krack P; Moro E; Castrioto A
    J Neurol Sci; 2019 Sep; 404():44-46. PubMed ID: 31325667
    [No Abstract]   [Full Text] [Related]  

  • 16. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

  • 18. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Idiopathic Parkinson's disease: practical hints for the treatment].
    Ludin HP
    Praxis (Bern 1994); 2005 Jul; 94(30-31):1147-50. PubMed ID: 16117469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of apomorphine in clinical practice.
    MacMahon DG
    Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.